This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/resource/domain/vavai/subjekt/
n18http://linked.opendata.cz/ontology/domain/vavai/
n8http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064203%3A_____%2F11%3A6982%21RIV12-MZ0-00064203/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n17http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064203%3A_____%2F11%3A6982%21RIV12-MZ0-00064203
rdf:type
skos:Concept n18:Vysledek
rdfs:seeAlso
http://www.ncbi.nlm.nih.gov/pubmed/21349484
dcterms:description
Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p = 0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p < 0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1295-1299) Several randomized studies and meta-analyses have suggested that pretreatment with statins may decrease periprocedural myocardial infarction (MI) in patients undergoing percutaneous coronary intervention (PCI). The purpose of this randomized study was to investigate the effect of a 2-day atorvastatin therapy before PCI on long-term clinical outcome. Two hundred statin-naive patients with stable angina pectoris referred for PCI were enrolled and randomized (ratio 1:1) to 2-day pretreatment with atorvastatin 80 mg/day and subsequent PCI (atorvastatin group), or immediate PCI (control group). The registry group comprised 182 consecutive patients on long-term statin therapy referred for immediate PCI during the same period as randomized patients. We compared the first occurrence of MI or death during long-term follow-up. There were no significant differences in most clinical characteristics and early results among the 3 groups. Median follow-up was 45 months (1 to 59). Incidences of death/MI were 11.4%, 12.9%, and 13.8% in the atorvastatin, control, and registry groups, respectively. In the same groups, age-adjusted estimated 4-year freedom from death/MI was 0.78 versus 0.75 versus 0.80, respectively (p = 0.882, log-rank test). In multivariate analysis, only age of patients (odds ratio 1.04, 95% confidence interval 1.02 to 1.07, p < 0.001) was identified as a significant predictor of death or MI during follow-up. In conclusion, these results suggest that 2-day therapy with high-dose atorvastatin before PCI did not influence occurrence of periprocedural MI or long-term clinical outcomes. (C) 2011 Elsevier Inc. All rights reserved. (Am J Cardiol 2011;107:1295-1299)
dcterms:title
Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention
skos:prefLabel
Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention Effect of Two-Day Atorvastatin Pretreatment on Long-Term Outcome of Patients With Stable Angina Pectoris Undergoing Elective Percutaneous Coronary Intervention
skos:notation
RIV/00064203:_____/11:6982!RIV12-MZ0-00064203
n18:predkladatel
n19:ico%3A00064203
n3:aktivita
n12:I n12:Z
n3:aktivity
I, Z(MZ0FNM2005)
n3:cisloPeriodika
9
n3:dodaniDat
n17:2012
n3:domaciTvurceVysledku
n10:5596602 n10:6141323 n10:3213803 n10:6681107 n10:6444296 n10:7970269 n10:2220172
n3:druhVysledku
n13:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n11:predkladatel
n3:idSjednocenehoVysledku
196549
n3:idVysledku
RIV/00064203:_____/11:6982
n3:jazykVysledku
n6:eng
n3:klicovaSlova
periprocedural myocardial-infarction; preprocedural statin therapy; randomized-trial; microembolization; metaanalysis; impact
n3:klicoveSlovo
n9:preprocedural%20statin%20therapy n9:microembolization n9:impact n9:metaanalysis n9:randomized-trial n9:periprocedural%20myocardial-infarction
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[B8A3C28E2934]
n3:nazevZdroje
American Journal of Cardiology
n3:obor
n7:FA
n3:pocetDomacichTvurcuVysledku
7
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n17:2011
n3:svazekPeriodika
107
n3:tvurceVysledku
Tomašov, Pavol Tesař, David Adlova, R. Malý, Martin Martinkovičová, Lucia Veselka, Josef Zemánek, David Hájek, Petr
n3:wos
000290605600008
n3:zamer
n8:MZ0FNM2005
s:issn
0002-9149
s:numberOfPages
5